Drilldown: Medicines

None (3)

Other values:

Search

None (78) · (none, never marketed) (1) · Aduhelm (1) · Dalmane (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Doral (1) · Doriden (1) · Halcion (1) · Hetlioz (1) · Imovane (1) · Kisunla (1) · Leqembi (1) · Lunesta (1) · Mogadon (1) · Nembutal (1) · Placidyl (1) · ProSom (1) · Quaalude (1) · Restoril (1) · Rohypnol (1) · Rozerem (1) · Seconal (1) · Sonata (1) · THIP (1) · Versed (1) · Xyrem (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

5-HT2A agonist (26) · GABAA positive allosteric modulator (15) · Potent 5-HT2A agonist (5) · None (4) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · GABAA positive allosteric modulator (non-benzodiazepine) (3) · Contains LSA (2) · Contains mescaline (2) · GABAA potentiator and direct activator (2) · Melatonin receptor agonist (2)

Other values:

Search

None (99) · Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. (1) · Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1) · Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023 (1) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1)

None (99) · 10 mg/kg IV every 2 weeks (1) · 700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance (1) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1) · Was 1 mg/kg IV q4w × 2, then 3 mg/kg × 2, then 6 mg/kg × 2, then 10 mg/kg q4w (1)

None (99) · 200 mg/2 mL, 500 mg/5 mL vials for IV infusion (1) · 350 mg/20 mL vial for IV infusion (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1) · Was: 170 mg/1.7 mL, 300 mg/3 mL vials for IV infusion (1)

None (99) · 10 mg/kg q2w (1) · 1400 mg q4w (1) · N/A (never approved) (1) · Withdrawn 2024 (1)

None (98) · intranasal; rectal and IV reported. (1) · IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting (1) · IV infusion every 4 weeks (2) · Oral (2) · sublingual (1)

None (98) · 30–60 minutes (1) · Amyloid PET clearance within months; cognitive benefit over 18 months (1) · PET Aβ reduction over months (1) · Slowing of cognitive decline over 18 months (modest effect, ~27% relative slowing) (1) · ~20–40 min PO; faster sublingual/intranasal. (1)

None (98) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · 8–12 hours (1) · Ongoing dosing (1) · Treatment can be discontinued upon achieving amyloid clearance (1) · Withdrawn (1)

None (98) · 3–5 hours (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) · ~12.1 days (1) · ~25 days (1) · ~5-7 days (1)

None (98) · 100% (IV) (3) · 70–90% (oral) (1) · Not formally characterized in humans. (1)

None (98) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Discontinued/withdrawn (1) · Limited data (2) · Not established (1)

None (99) · Rx; ARIA monitoring required (1) · Rx; REMS-like program for ARIA monitoring (1) · Schedule I (United States) (1) · Withdrawn from US market January 2024 (1)